is copper tripeptide 1 the same as ghk cu GHK-CU Tripeptide-1 - GHKCUCTP1-001 GHK-Cu — research peptide |

#siliconvalley #new #defense #techstartups #neoprimes #anduril #palantir #mva #milvet #pulling #drawing #billions #funding #reshaping #america #nationalsecurity #challenging #dominance #legacy #contractors #primes #lockheedmartin #raytheon #northropgrumman #generaldynamics #boeing To view or add a comment, sign in Auterion Raises $130M to Become the Microsoft for Drones The defense-tech startup Auterion has secured $130M in fresh funding, pushing its valuation past $600M

Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research

The results differ significantly by administration route: topical serum, topical post-microneedling, and supervised subcutaneous injection produce different outcomes, with injectable 503A compounded GHK-Cu producing the most consistent and comprehensive results in clinical settings

GHK-Cu, on its own, is hard to use and is typically an ingredient mixed into a formula

The difference is that GHK-Cu activates it biochemically, systemically, and without requiring physical tissue injury

Rather than morning administration competing with the growth hormone peak stimulated by secretagogues (often administered at night), AOD-9604 moves to morning while CJC-1295/Ipamorelin administers before bed